UPDATE 2-U.S. objects to Glaxo, Novartis drug promotions

* FDA releases three letters to companies

* Cancer, pain, bladder drug promotions cited

* Website, e-mail, journal ad draw complaints
(Adds Glaxo, Novartis comments)

WASHINGTON, April 16 (BestGrowthStock) – GlaxoSmithKline Plc
(GSK.L: ), Novartis AG (NOVN.VX: ) and Astellas Pharma Inc (4503.T: )
used misleading promotions for cancer, pain and bladder drugs,
U.S. regulators said in letters released on Friday.

A medical journal advertisement by Glaxo “omits important
information” about the safety and effectiveness of cancer drug
Arzerra, the Food and Drug Administration said in a letter to
the British drugmaker.

In a separate letter, the FDA said a promotional webpage
had overstated the effectiveness of Glaxo’s and Astellas
Pharma’s (4503.T: ) overactive-bladder drug Vesicare.

The agency also said a Novartis email to consumers had made
misleading claims about pain reliever Voltaren gel.

GlaxoSmithKline has removed the content that drew FDA
complaints from the Vesicare website and will not use the
Arzerra ad again, company spokeswoman Mary Anne Rhyne said.

“We take the FDA’s concerns seriously” and “are working to
resolve any remaining questions and ensure our materials
reflect the direction provided by the FDA,” she said.

A Novartis spokeswoman said the company was reviewing the
FDA’s letter and would with work with the agency to address
concerns.

An Astellas spokeswoman did not immediately respond to a
request for comment.

Stock Market Investing

The FDA posted the letters at
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm197224.htm.
(Reporting by Lisa Richwine, editing by Gerald E. McCormick
and Lisa Von Ahn)

UPDATE 2-U.S. objects to Glaxo, Novartis drug promotions